EU regulates to match medicines to children

Although the way adults react to drugs is often not the same for children, there are no special trials to check the suitability for smaller size patients.

This is set to change from 2007, because EU ministers for the environment have given the go-ahead for a regulation that stipulates that medicines will have to be tested for their particular risks and side effects in children. In return, drugs manufacturers will receive a six-month extension of patents for their products, to give them an advantage over manufacturers of cheaper, ‘copy-cat’ generic medications.
Once the regulation comes into force, all medicines already on the market will have to be retrospectively licensed for children’s prescriptions.

The European Parliament has been asking for this new regulation for years. Up until now, many medicines have only been adapted to suit children by administering lower  doses; however, many experts think there is an inherent risk of unforeseen side effects.

Peter Liese, a medic, and member of the European Parliament and the German Christian Democratic Union, said that, apart from medicines such as cough mixture, medications for serious illnesses, such as cancer or AIDS, have not yet been specifically licensed for children. Doctors often refrain from giving their small patients the necessary medication because they are concerned about unforeseen side effects. Scientifically-based recommendations from manufacturers could alleviate those fears.
Source: www.medical-tribune.de

14.11.2006

More on the subject:

Related articles

Photo

Sponsored • On-demand Webinar

Pharmaceutical Press shares the most common types of medication errors

In this on-demand webinar, participants will learn how to safely administer drugs to patients with swallowing difficulties or enteral feeding tubes, including injectable drug compatibility.

Photo

News • Promising trial results from Spain

Clot-dissolving drug after thrombectomy may improve stroke recovery

Even after a blood clot is removed from a large brain artery via thrombectomy, administering the thrombolytic drug alteplase to the area may improve stroke recovery, a new trial from Spain shows.

Photo

News • Study finds faster regain than ending diet programmes

GLP-1 discontinuation: weight-loss drugs work – until you stop

Drawbacks of GLP-1 discontinuation: People tend to regain weight rapidly after stopping weight-loss drugs - and faster than after ending behavioural weight loss programmes - according to new research.

Subscribe to Newsletter